Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE trial in mid-to-low rectal cancer using neoadjuvant CapeOx + bevacizumab + serplulimab with TAMIS
ChiCTR2600134315Phase 2Not yet recruiting
- Sponsor
- Chengdu Shangjin Nanfu Hospital
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, bevacizumab and serplulimab in rectal adenocarcinoma and rectal cancer, sponsored by Chengdu Shangjin Nanfu Hospital. Primary endpoint: Pathological complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
capecitabineoxaliplatinbevacizumabserplulimab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ChiCTR2600134315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134315.